Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of BMS-986165 in moderate to severe plaque psoriasis
MOH_2020-04-16_007393Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: Long-term safety and Long-term efficacy. Started Mar 2020; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2020-04-16_007393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-16_007393.